Abstract
In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodefciency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses.
Author supplied keywords
Cite
CITATION STYLE
Kleinstein, S. E., Shea, P. R., Stamm, L. M., Sulkowski, M., Goldstein, D. B., & Naggie, S. (2018). Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism with Hepatitis C Virus (HCV) Treatment Relapse among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. Clinical Infectious Diseases, 66(12), 1953–1956. https://doi.org/10.1093/cid/cix1051
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
